Brooks Laboratories Submits Q4FY26 SEBI Compliance Certificate to Stock Exchanges

Brooks laboratories has submitted its quarterly compliance certificate to BSE Limited and National Stock Exchange of India for the quarter ended 31st March 2026. The filing, made on 10th April 2026, fulfills the company's obligations under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Details

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. Company Secretary and Compliance Officer Krutika Rane (Membership no: 66310) signed the submission on behalf of Brooks Laboratories Limited.

Parameter	Details
Reporting Period	Quarter ended 31st March 2026
Filing Date	10th April 2026
BSE Scrip Code	533543
NSE Symbol	BROOKS
Registrar	MUFG Intime India Private Limited

Certificate Confirmation

The registrar's certificate, signed by Ashok Shetty, Sr. Vice President – Corporate Registry, confirms compliance with SEBI's depositories regulations. The document states that securities received from depository participants for dematerialization during the quarter were properly processed within prescribed timelines.

A notable aspect of this quarter's filing is that MUFG Intime India Private Limited reported no dematerialization or rematerialization requests were received during the Q4FY26 period. This indicates stable shareholding patterns with minimal movement between physical and electronic form of securities.

Corporate Information

Brooks Laboratories Limited operates from its corporate office located at 201, The Summit Business Bay, Behind Guru Nanak Petrol Pump, Off Andheri Kurla Road, Andheri (E), Mumbai. The company maintains its listing on both major Indian stock exchanges, ensuring compliance with all regulatory requirements for transparency and investor protection.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.99%	-10.70%	+22.26%	-46.79%	-52.50%	-13.70%

Brooks Laboratories Limited has issued a clarification to BSE Limited regarding recent movement in its share price, responding to an inquiry from the stock exchange dated April 1, 2026. The pharmaceutical company addressed concerns about price volatility under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Regulatory Compliance Statement

The company confirmed it has disclosed all material information with bearing on operations and performance to the stock exchange within stipulated timeframes. Brooks Laboratories emphasized adherence to necessary disclosures in accordance with SEBI Listing Regulations.

Parameter	Details
Communication Date	April 2, 2026
BSE Reference	L/SURV/ONL/PV/APJ/2026-2027/3482
Regulation	SEBI Listing Obligations Regulation 30
Scrip Code	533543

Price Movement Clarification

Brooks Laboratories stated it holds no pending unpublished price sensitive information that may influence price or volume behavior in the scrip. The company management declared no awareness of specific reasons behind significant share price changes.

The pharmaceutical firm attributed share price movement and trading volumes to market-driven factors, emphasizing management has no connection with price changes. Company Secretary and Compliance Officer Krutika Rane signed the response, reiterating the organization's commitment to regulatory compliance.

Corporate Governance Commitment

The company assured continued adherence to compliance requirements under Listing Regulations and other applicable laws. Brooks Laboratories maintains its corporate office at The Summit Business Bay, Andheri East, Mumbai, and operates under the oversight of Company Secretary Krutika Rane (Membership No. 66310).